Chemoresistance is an important concern in the treatment of metastatic colon cancer. It may emerge through selection of clones that are inherently resistant from the outset or through mechanisms acquired during treatment. Cell fusion represents an efficient means of rapid phenotypic evolution that make cells with new properties at a rate exceeding that achievable by random mutagenesis. Here, we first identified a number of proteins involved in cell fusion using a shotgun proteomics approach, then we investigated the role of these proteins namely tetraspanin CD81/CD9, ADAM10, GTP-binding protein a13, radixin, myosin regulatory light chain and RhoA in the regulation of colon cancer cell fusion. We also found a previously unrecognized role of ADAM10, Ga13 and RhoA in promoting cell fusion. Finally, we show that the occurrence of cell fusion in a metastatic model of colon carcinoma causes the appearance of cells resistant to both 5-fluorouracil and oxaliplatin. These findings highlight the importance of cell fusion in cancer progression and raise significant implications for overcoming chemoresistance in metastatic colon cancer.
INTRODUCTION
Survival times of patients with advanced colon cancer have increased over the last decade, primarily as a result of treatment with combinations of cytotoxic agents. However, the clinical benefits of these therapies are short-lived and restricted to subgroups of patients. Resistance to cytotoxic drugs is the main cause of therapeutic failure, which usually recurs with a multidrug resistance (MDR) phenotype shortly after dramatic response to initial treatments. Some molecular mechanisms of drug resistance are known. Two well-characterized drug efflux pumps, P-glycoprotein and MDR-related protein, have been thought to be crucial for MDR. However, the importance of these mechanisms remains still controversial. For example, ectopic expression of these pumps induces partial resistance in comparison with that achieved by long-term drug selection. 1, 2 Clinical studies have also revealed that expression of these pumps was rarely observed and did not necessarily correlate with the outcome in colon cancer. 3 Therefore, these proteins cannot completely account for the appearance of a MDR phenotype of colon cancer and other mechanisms must be involved in this process. 5-Fluorouracil (5-FU), leucovorin and oxaliplatin (Oxa) represent a therapeutic regime (FOLFOX) commonly used in the treatment of patients with advanced colon cancer. [4] [5] [6] Resistance to therapy occurs in nearly all patients with metastatic colon cancer, and patients that acquire resistance have a disease progression with few therapeutic options. As the gain of drug resistance involves the acquisition of a new phenotype, we hypothesized that the generation of fused cells in metastatic colon cancer could represent a phenomenon responsible of MDR. In recent years, accumulating experimental evidence has suggested a possible broad involvement of cell fusion during the initiation, progression and phenotypic diversification of cancer. [7] [8] [9] Cell fusion is a process in which two cells become one by merging their plasma membranes. [10] [11] [12] The role of cell fusion in metastasis has been recently demonstrated. This represents an efficient means of rapid phenotypic evolution during tumor progression that make cells with new properties at a rate exceeding that achievable by random mutagenesis. 13 In spite of the diversity of cell types that undergo fusion, the underlying cellular processes, including cell-cell adhesion, alignment and membrane mixing, are similar irrespective of the cell type. 14 In this regard, tetraspanins and ADAMs (A Disintegrin And Metalloprotease domain) proteins have been implicated in cell fusion processes. In particular, tetraspanin CD9 and CD81 have been implicated in muscle cell fusion, mononuclear phagocytes and linked to the virus-induced syncitium formation. [15] [16] [17] ADAMs were initially discovered as proteins involved in fertilization, muscle fusion and organ development. 18, 19 In this study, we provide evidence that proteins ADAM10, GTP-binding protein a13, radixin, myosin regulatory light chain and RhoA promote cell fusion in colon cancer cells. In addition, we demonstrate that cell fusion results in the acquisition of a resistant phenotype to both 5-FU and Oxa, two pharmacological agents commonly employed in the treatment of advanced colon cancer.
RESULTS
Identification of distinct proteins associated with CD81 by shotgun proteomics Because of the implication of tetraspanin CD81 in cell fusion and in an attempt to identify and characterize the proteins associated with CD81, we immunoprecipitated CD81 from Triton X-100 cell lysates of human colon cancer cells, SW480. To eliminate background proteins not effectively associated with CD81, we used an IgG1 antibody as control. Any protein identified in both conditions was not considered as a protein associated with CD81. The immunoprecipitated proteins were digested with trypsin and peptides were subsequently identified by shotgun proteomics. 20 The proteomic analysis led to the identification of 51 proteins (Supplementary Information Table S1 ). We found different classes of molecules associated to CD81, including tetraspanin CD9, molecules mediating adhesion with extracellular matrix (that is, integrins), cell-cell adhesion (that is, EpCAM, CD44), signaling proteins (that is, heterotrimeric G protein subunits) and the disintegrin-like metalloproteinase ADAM10. Of the proteins identified in this screen, CD81, CD9 have been implicated in cell fusion, whereas less is known about the role of ADAM10. First, we verified the cellular colocalization of CD81 and CD9 with ADAM10 in SW480 by immunofluorescence and found that CD81 and CD9 colocalize with ADAM10 in punctuate structures (Figure 1a) . Then, we addressed the cellular colocalization of CD9 with ADAM10 in the CD81-negative murine colon cancer cells, CT26. Similarly, these cells showed a robust colocalization of CD9 with ADAM10 in punctuate structures (Figure 1b) . The next step was to assess the physical interaction of CD81 and CD9 with ADAM10 by immunoprecipitation experiments. These revealed that CD81 and CD9 are indeed associated with ADAM10, a protein migrating at 78 kD under nonreducing conditions (Figure 1c ). Most ADAMs, including ADAM10, possess the typical HEXGHXXGXXH motif at their catalytic site, which is responsible for the zinc-dependent protease activity. We therefore assessed the presence of proteolytitc activity associated with CD81 and CD9 by using gelatin zymography. The detection of a collagenolytic band migrating at B78 kD confirmed the presence of ADAM10 in the CD81/CD9-immunoprecipitated complexes (Figure 1d ). Colon carcinoma cell fusion is promoted by ADAM10 that is stably associated to CD81 and/or CD9 We focused our attention on the role of ADAM10 and its structural domains in regulating cell fusion. Hence, we cloned a bovine ADAM10 cDNA, whose amino-acidic sequence is identical to the human ADAM10, into a plasmid expressing a monomeric red fluorescent protein tagged to ADAM10 (ADAM10-RFP). The ADAM10-RFP cDNA was then ectopically expressed in CT26. We observed the appearance of binucleate or multinucleate CT26 cells when the ADAM10-RFP-transfected CT26 cells were grown in the presence of geneticin, an antibiotic used to select ADAM10-RFP stable transfectants (Supplementary Information Figure S1A ). We assumed that this aspect was allegedly due to cell fusion and eventually enhanced by ADAM10 overexpression. Therefore, we next evaluated whether the multinucleated phenotype induced by ADAM10 was restricted only to CT26 cells or whether this was a more general phenomenon. To this end, human colon cancer cells HCT116 not expressing CD81 were stably transfected with ADAM10-RFP and evaluated for the presence of the multinucleated phenotype as performed with ADAM10-RFP-CT26 transfectants. Similar to CT26, HCT116 cells expressing ADAM10-RFP showed the presence of multinucleated cells (Supplementary Information Figure S1B ). These findings indicate that ectopic expression of ADAM10 increased the fusogenic competence in both human and murine colon cancer cell types.
To further substantiate the involvement of ADAM10-RFP in promoting cell fusion, we co-cultured CT26-EGFP stable transfectants with CT26-ADAM10-RFP stable transfectants for 2 days. To visualize cell fusion, we take advantage of live-cell imaging. We therefore seeded an equal number of untransfected and ADAM10-RFP-transfected CT26 cells onto a layer of Matrigel and performed time-lapse confocal microscopy for 18 h (64 800 s). The cell mixture was imaged by capturing a single confocal section at the indicated times. A representative animated sequence of the imaged cells is shown in supplementary information Movie S1. As shown in Figure 2c , the cell-cell contact between ADAM10-RFP-CT26 transfectants and untransfected CT26 resulted, in this latter, in altered cell shape (upper and middle panels) and in a disruption of the cell membrane followed by cell fusion (lower panels). Taken together, these results imply that expression of ADAM10 promotes cancer cell fusion.
Reduced expression of CD9 increases cell fusion in the CT26 and HCT116 cells The role of CD81 and CD9 in cancer cell fusion is at the present barely defined, therefore, we tested whether inhibition of CD9 expression in the CD81-negative CT26 and HCT116 cells would affect their fusion ability. To do so, we used a short hairpininterfering RNAs (shRNA) targeted against the coding region of the mouse and human CD9 gene. As shown in Figure 3a , expression of CD9-shRNA results in a reduction of both mRNA and CD9 protein expression levels in CT26 cells as evaluated by flow cytometry and RT-PCR, respectively. A control-shRNA (CTL-shRNA) did not cause a reduction of CD9 expression (Figure 3a) . Similarly, expression of CD9-shRNA results a reduction of both mRNA and CD9 protein expression levels in HCT116 cells (Figure 3b) . Notably, the reduced expression of CD9 enhanced the percentage of fused cells in both CT26 and HCT116 cell lines in comparison with CT26 and HCT116 transduced with control-shRNA. Collectively, our data suggest that the presence of CD9 may prevent colon cancer cell fusion.
Cysteine-rich domain of ADAM10 is required for CD81 and CD9 association with ADAM10 and supports colon carcinoma cell adhesion The findings that ADAM10 promotes cell fusion of CT26 and HCT116 prompted us to investigate whether carcinoma cells attached to the extracellular portion of ADAM10. To study the involvement of ADAM10 domains in promoting cell adhesion, we performed experiments using recombinant ADAM10 truncation mutants and different colon carcinoma cell lines (CT26, SW480 and HCT116). In particular, the recombinant domains of ADAM10 were tagged with EGFP at COOH terminus to allow their detection, and then expressed in COS-7 cells (Figure 4a ). To determine the interaction of the recombinant mutants of ADAM10 with tetraspanin CD81, we took advantage by the fact that COS-7 cells were negative for CD81 expression. Hence, we co-expressed EGFPtagged ADAM10 mutants and the human pcDNA 3.1 vector harboring CD81 in COS-7 cells. The physical association was then analyzed by co-immunoprecipitation in both cell lysates and culture medium supernatants. As shown in Figure 4b , CD81 was detected in immunoprecipitates from cells expressing full-length ADAM10 (ADAM10-EGFP), disintegrin and cysteine-rich domain and cysteine-rich domain alone (Cys-EGFP) but not in those expressing the transmembrane and intracytoplasmic domain (TMCyt-EGFP). Interestingly, we detected the presence of endogenous CD9 in the immunoprecipitates of these variants. This is in agreement with a previous study showing that microvesicles containing both CD81 and CD9 are released by cells in the culture medium. 21 These results clearly demonstrate the association of CD81 and CD9 with ADAM10. Even more important, our data elucidate a crucial role for the cysteine-rich domain of ADAM10 in mediating association with CD81 and CD9.
A fundamental feature of cell fusion is the juxtaposition of two plasma membranes. To evaluate a possible involvement of ADAM10 in this process, we addressed the ability of CT26 to interact with ADAM10. As shown in Figure 4c , CT26 cells attached to: (1) recombinant disintegrin and cysteine-rich domain, (2) cysteine-rich domain alone and (3) full-length ADAM10. No cell attachment was observed to the transmembrane/cytoplasmic domain. A similar adhesion pattern was observed in analog experiments carried out with SW480 and HCT116 cells.
ADAM10 and CD81 regulate localization of GTP-binding a13
We hypothesize that tetraspanin CD81 and CD9 and ADAM10 contribute to bringing the opposing membranes into close proximity in fusogenic cancer cells and that, in a subsequent step, these proteins can recruit intracellular proteins forming multi-protein complexes at the sites of fusion. To explore this hypothesis, we went back to our proteomic data and focused on GTP-binding protein a13. Ga13 acts as a signal transducer for G protein-coupled receptor as well as for non-G protein-coupled receptor. As illustrated in Figure 5a , ADAM10 and CD81 showed a prominent colocalization with Ga13 in SW480 cells. A robust colocalization of ADAM10 and CD9 was also observed in CT26 cells (Figure 5b ). To learn more about the localization of Ga13, we cotransfected a RFP vector with CD81-GFP, as shown in Supplementary Information Figure S2A , and a RFP-tagged Ga13 with CD81-GFP (Supplementary Figure S2B) . We observed colocalization of RFP-Ga13 with CD81-GFP at cellular cortex and induction of cell rounding in CT26 and HCT116 cultured on a twodimensional glass-bottomed dishes (Supplementary Figure S2B) . These data clearly indicate that Ga13 takes part in the plasticity of the plasma membrane and the remodeling of the cytoskeleton.
However, a fundamental question remained about how CD81 and ADAM10 are organized in paired living cells plunged in a three-dimensional substrate. To this end, we cotransfected CT26 cells with CD81-GFP and RFP-Ga13, suspended them in gelled Matrigel and immediately analyzed by fluorescence microscopy. An equal number of non-labeled CT26 and CT26 expressing ADAM10-RFP (red) were mixed, included into a layer of Matrigel and immediately analyzed by time-lapse confocal microscopy for 18 h (see also Supplementary Information, Movie S1). The cell mixture was imaged by capturing a single confocal section at the indicated times (30 min each). Cell-to-cell contact of a CT26 expressing ADAM10-RFP (red) with a non-labeled CT26 is indicated with a white arrow. Cell fusion was observed between a positive ADAM10-RFP-CT26 cell and a non-RFP-labeled CT26 cell. In non-RFP-labeled CT26 cells, the cell-to-cell contact leads to cell shape modifications (upper and middle panels) and consecutively to disruption of the cell membrane (lower panels). In the last panel, immediately after the fusion, ADAM10-RFP was localized in the cytosol of the non-labeled CT26 cell, indicating an exchange of the ADAM10-RFP between cells. Scale bars 20 mm.
Cell fusion promotes chemoresistance V Carloni et al
As shown in Supplementary Figure S3A , we noticed a significant colocalization of both proteins CD81 and Ga13 to the juxtaposition of cell membrane. Next, we evaluated the cellular localization of ADAM10-RFP and CD81-GFP (Supplementary Figure S3B) . We observed that ADAM10-RFP is localized in both intracellular vesicles and at cell-cell contact, and that this cellular distribution was paralleled by CD81-GFP. Similarly, colocalization of ADAM10-RFP with EGFP-Ga13 was evident around the cell membrane confirming in living cells the findings observed analyzing the endogenous proteins (Supplementary Figure S3C) .
Interaction of SW480 and CT26 with ADAM10 stimulates RhoA activity As the interaction of Ga13 with RhoA leads to an increase in cell cortical tension as well as in disruption of plasma membrane-cortical actin, 22, 23 we investigated whether the interaction of SW480 and CT26 cells with ADAM10Cys-EGFP or ADAM10-EGFP activates Rho small GTPase. To this end, we performed a GTP-RhoA pull-down assay. First, we observed a colocalization of endogenous CD81 with RhoA to the plasma membrane in SW480 and CD9 with RhoA in CT26 cells (Figure 6a) . Similarly, endogenous ADAM10 is colocalized with RhoA to the plasma membrane in SW480 and CT26 cells (data not shown). Second, SW480 and CT26 cells stimulated with ADAM10Cys-EGFP or ADAM10-EGFP resulted in increased levels of GTP-RhoA. Increased levels of GTP-RhoA were also obtained with the ectopic expression of Ga13 in the same cell lines (Figure 6b ). These data indicate that CD81/CD9/ADAM10 or CD9/ADAM10 complexes stimulates RhoA activity in interacting cells and disclose an involvement of Ga13 in this process. Cell fusion promotes chemoresistance V Carloni et al ADAM10 causes Ga13-dependent myosin light-chain phosphorylation in colon carcinoma cells The cell cortex is a network of cross-linked actin filaments whose tension levels are modified by external or internal cues. The cortical tension in cancer cells is mainly regulated by phosphorylation of the myosin light chain 2, also referred to as myosin regulatory light chain. Thus, we evaluated the levels of phosphomyosin light chain 2 (Ser19) in SW480 and CT26 cells after plating onto dishes coated with ADAM10Cys-EGFP or ADAM10-EGFP. We found that SW480 and CT26 plated on ADAM10-EGFP-coated dishes display increased levels of MLC2 phosphorylation, whereas cells lacking Ga13 as a consequence of knockdown by siRNA showed a remarkable reduction of phosphorylation of the myosin light chain 2 (Ser19) (Figures 6a and d) . These data clearly demonstrate that the interaction of cells with ADAM10 causes phosphorylation of MLC2 and that the interaction of Ga13 with RhoA positively influences this final event leading to an increase in myosin ATPase activity and cell contraction. 24 Reduced phosphorylation levels of ERM proteins following interaction of SW480 and CT26 with ADAM10 Cortical contractility is exceptionally high in tumor cells and the tension build up can induce disruption of the cell cortex at sites where plasma membrane and cortical actin interactions are locally reduced. In this regard, the ERM proteins (ezrin, radixin and moesin) function as linkers between the plasma membrane and the actin cytoskeleton, thus providing structural strength to the cell cortex. 25 Phosphorylation at a carboxy-terminal threonine residue (Thr567 of ezrin, Thr564 of radixin, Thr558 of moesin), which disrupts their amino-and carboxy-terminal association, has a key role in modulating the conformation and function of ERM proteins. 26 To this end, we evaluated the phosphorylation levels of ERM proteins using SW480 and CT26 cells plated onto ADAM10Cys-EGFP-or ADAM10-EGFP-coated dishes or maintained in suspension. As shown in Figure 6e , cells plated onto plastic revealed the presence of two phosphorylated proteins. In particular, the upper band corresponding to radixin/ezrin was strongly phosphorylated in both SW480 and CT26 cell lines. Conversely, when the cells were plated onto ADAM10Cys-EGFP and ADAM10-EGFP or maintained in suspension for 60 min phosphorylation of proteins was undetected. Taken together, these data suggest that the interactions of CD81/CD9/ADAM10 or CD9/ADAM10 complexes in opposing fusogenic cancer cells increase cortical tension and initiate events of cortical actin membrane destabilization at the cell-cell contact that eventually induce cell fusion. Thus, to analyze a possible involvement of Ga13-Rho pathway in the aforementioned mechanism, we used a dominant-negative variant of Rho (N19RhoA), in which Ser19 is changed to Asn (N). The ectopic expression of N19RhoA has been demonstrated to inhibit endogenous Rho function and the Ga13-RhoA pathway by forming non-productive complexes with guanine nucleotide exchange factors (GEFs) for Rho. 27 The ectopic expression of N19RhoA significantly reduced the percentage of fused CT26 cells whereas the expression of control acGFP1 vector had no effect (Figure 6f ).
Appearance of drug resistant to both 5-FU and Oxa as a consequence of cell fusion in metastatic colon carcinoma We next sought to investigate the involvement of cell fusion in selecting chemoresistant cells to 5-FU and Oxa in metastatic colon spontaneously with CT26-5FUR in vivo. In addition, the ectopic expression of cysteine-rich domain ADAM10 increased the number of fused cells resistant to both 5-FU and Oxa in liver metastases from colon cancer (Figure 7c ). We observed an average fusion percentage of 9.8% in RFP þ /GFP þ mixed cell population and 18.4% in RFP þ /AD10CysGFP þ (Figure7d). Taken together, these data demonstrate the occurrence of cell fusion in metastatic colon carcinoma as well as the involvement of cell fusion in the appearance of tumor cell subpopulations resistant to both 5-FU and Oxa.
DISCUSSION
Colon cancer can usually be cured by surgical excision at any stage before metastases to distant sites (i.e., liver, lung) are established. Understanding the basic aspects of this process has obvious and important implications for clinical research. However, many questions still remain. For example, how many mutations are required for a particular metastatic cell population to acquire a widespread chemoresistance? Recent studies have established that the great majority of the mutations present in metastases are also present in the primary colon carcinoma. In addition, the process of ex vivo cell culture of tumors excised from patients does not introduce new mutations into colon tumor cell populations. 28, 29 It is reasonable that an alternative mechanism must be involved in this process and that, in this context, cell fusion contributes to widespread chemoresistance by combining genes responsible for resistance to various drugs. Here, we have shown that cell fusion is driven by ADAM10 in colon carcinoma and this induces chemoresistance to both 5-FU and Oxa. Fusion between tumor cells with distinct phenotypes can generate cells with new properties at a rate exceeding that achievable by random mutagenesis, thereby allowing a better adaptation to survive to the therapeutic treatments. Metastatic subpopulations might thus be more able to evolve under selective pressures than nonmetastatic cells, by a process other than mutation. 30 Recent findings showing that chronic inflammation dramatically increases the frequency of cell fusion of hematopoietic cells with various cell lineages 31, 32 may account for the high fusogenicity of metastatic tumor cells, as inflammation is often associated with the tumor microenvironment and metastatic cells may trigger an inflammatory response once they colonize the liver. Recently, it has also been described that metastatic tumor cells are able to induce TNF-a production by Kupffer cells and these latter constitute the major source of TNF-a in tumor cell-inoculated livers. 33 In agreement with the aforementioned observations, our results show that metastatic cancer cells fuse spontaneously in vitro and in vivo. This is in line with another recent report by Lu and Kang showing that organotropisms of metastatic cells can be acquired through spontaneous fusion between cancer cells with bone and lung tropism that eventually generates populations of cells capable of metastasizing to both organs. 13 Finally, our study discloses a mechanism by which ADAM10 promotes fusion in colon cancer cells. Along this line, we propose that in a context of fusogenic cancer cells, ADAM10 may initiate a combination of events that lead to local disruption of interactions between plasma membrane and cortical actin and the consequent plasma membrane fusion. The role of ADAM10 in regulating plasma membrane-cortical actin at sites of cell-cell contact is particularly important in three-dimensional environments and in vivo. In addition, our study highlights that enhanced expression of ADAM10 in colon cancer cells has biological consequences that can be attributed to the presence of additional non-catalytic ADAM10 domains (i.e., cysteine-rich domain). This further implies that not all functions of ADAM10 in colon cancer cells will be abolished by effective protease inhibitors. Here we have also found that both Ga13 and Rho activity contribute to cell fusion through an increase in cell cortical tension as well as in disruption of plasma membrane-cortical actin interactions. Our study demonstrates not only the implication of ADAM10 in stimulating Ga13-mediated activation of RhoA and phosphorylation of myosin regulatory light chain, but it also shows a Ga13-dependent regulation of ERM proteins. It has been reported that Ga13 directly interacts with radixin, a member of ERM proteins, and that this interaction results in a conformational activation of radixin. 34 This phenomenon is possibly due to competition between components of the Rho signaling pathway (for example, p115 Rho GEF) and radixin for Ga13 binding, (see Figure 8 ). Finally, these findings emphasize the role that ADAM10 and the cytoskeleton play in promoting metastatic cancer cell fusion.
In conclusion, this study demonstrates a crucial role for cell fusion in colon carcinoma that makes cancer cells more resistant to conventional chemotherapeutic agents. The information derived from this study may have two relevant immediate consequences in the development of more efficient pharmacological strategies against metastatic colon cancer. First, the possibility of targeting hidden actions of multi-task metalloproteases such as ADAM10, and particularly its contribution to cancer cell fusion. Second, a better understanding of the biology of fused cancer cells will contribute to identify and employ specific inhibitors in the treatment of colon cancer.
MATERIALS AND METHODS
Cell lines and antibodies SW480 and HCT116 human colon carcinoma cell lines, CT26 murine colon carcinoma cell line were purchased from ATCC (Rockville, MD, USA). Cos-7 cells were from ATCC.
Expression of ADAM10 truncation mutants
The plasmid pcDNA3-ADAM10 coding for wild-type bovine ADAM10 (GenBank: Z21961.1) was used as template to clone and insert ADAM10 
Cell adhesion assay
Cell culture 24-well plate were coated with an anti-EGFP antibody by placing the antibody dilution (30 mg/ml) in the well plate. 35 The plate was gently rocked overnight at 4 1C before the solution was aspirated. The protein binding sites of each well was blocked with sterile phosphate-buffered saline (PBS) containing 3% (w/v) BSA for 60 min at 37 1C. The blocking solution was aspirated and replaced with PBS as control or supernatant of Cos-7 transfected with ADAM10-EGFP, ADAM10DisCys-EGFP, ADAM10Cys-EGFP or ADAM10TMCyt-EGFP. The coating with supernatant was performed at 37 1C for 60 min. After a rinse with PBS, 500 ml of the cell suspension (5 Â 10 4 /ml) was added to the wells for 60 min at 37 1C. The plate was rinsed twice in serum-free Dulbecco's modified Eagle medium and the cells fixed for 5 min in methanol, rinsed in PBS and stained with 0.1% crystal violet in 10% methanol (vol/vol). Absorbance was measured with an ELISA reader (Bio-Rad, Hercules, CA, USA) at 590 nm. A blank value corresponding to an empty well was automatically subtracted.
Flow cytometry and time-lapse confocal microscopy
For flow cytometry analysis, CT26 or HCT116 stable transfectants expressing EGFP or ADAM10-RFP were obtained by selection with geneticin. CT26-EGFP stable transfectants (10 6 cells) were mixed with CT26-ADAM10-RFP stable transfectants (10 6 cells) in the presence of geneticin. Fused cells were identified by dual color FACScan. For time-lapse microscopy experiments, we suspended an equal number of untransfected CT26 cells with ADAM10-RFP-transfected CT26 cells onto a layer of Matrigel plated on 60-mm glass-bottomed cell culture plates. Live imaging was performed at 37 1C using a Leica TCS SP2 confocal microscope with an aerated incubation chamber for long-term experiments with living cells. For immunofluorescence microscopy, cells were washed with PBS, fixed with 2.5% paraformaldehyde for 10 min, and then blocked 1 h with 3% goat normal serum in 0.05% Triton X-100. Cells were sequentially incubated with primary and Cy3-or Cy2-conjugated secondary antibodies.
Retroviral infections
We cloned by PCR the EcoRI-and SalI-flanked insert from plasmid pRetroQ ADAM10-GFP containing ADAM10 Cys-rich domain-GFP cDNA into retroviral vector pBabe-puro (Addgene, Cambridge, MA, USA). Furthermore, we cloned the EcoRI and XhoI-flanked fragment from vector pRetroQDsRed monomer (Clontech), containing the full-length monomeric RFP cDNA, into retroviral vector pLXSN (Clontech).
Cell fusion in a syngeneic model of murine colon cancer metastasis
The cell lines CT26-OxaR and CT26-5FUR resistant, respectively, to chemotherapeutic drugs Oxa and 5-FU were obtained by selection in increasing concentrations of Oxa 10-25 mM and 5-FU 7.5-15 mM. CT26-OxaR and CT26-5FUR were infected with virus-containing supernatant and observed at least for two passages in vitro to verify that fluorescence intensity was stably expressed. CT26-OxaR expressing RFP, CT26-5FUR expressing GFP, CT26-5FUR expressing ADAM10 CysGFP or an equal mixture of these cells were injected into mice. Six-week-old male BALB/c mice were purchased from Charles River Laboratories (Lecco, Italy) and liver metastases were generated by intrasplenic injection of 1 Â 10 5 cells in PBS (50 ml). After 2 weeks, the livers were removed and the extracted metastases plated on dishes were cultured under sterile conditions. Outgrown cells were treated for a week with both 25 mM of Oxa and 15 mM of 5-FU to select for resistant cells and the survival cells were analyzed by dual color flow cytometry.
Statistical analysis
All data are expressed as means ± s.d. Statistical analysis was performed by Student 0 s t-test (analysis with GraphPad Prism). 
